State Street’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
AIM
MCMU
State Street's RXRX Position: Q2 2026 in Review
State Street increased its Recursion Pharmaceuticals (RXRX) stake by 22% in Q2 2026, buying an estimated $20.7M and bringing the position to 34,706,130 shares worth $127M. The position accounts for ﹤0.01% of the portfolio, ranked #1337.
State Street first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.
- State Street held 34,706,130 shares of Recursion Pharmaceuticals worth $127M as of Q2 2026.
- State Street bought 6,215,492 Recursion Pharmaceuticals shares in Q2 2026, an estimated $20.7M.
- Recursion Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1337 holding.
- State Street first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
- 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.